|
conclusion from paper suggesting use of RTPCR to determine ER status more accurately
We expect that the cost effective, extremely sensitive, high though-put molecular assay which requires only a few cancer cells could be an assay of choice to replace IHC in clinical labs for determining ER? status in breast cancer tissues once established in a multi-centered prospective clinical study.
Let's hope it happens soon.
|